alfavetalfavet

A fund advised by NORD Holding is acquiring a stake in the alfavet Group, headquartered in Neumünster and the market leader for veterinary medicines and nutraceuticals in the German veterinary channel. Together with CEO and shareholder Konstantin Wree, NORD Holding intends to develop alfavet into the leading European animal health platform. The existing shareholders underline their confidence in the company’s future through a continued financial commitment.

Since its foundation in 2003, alfavet has become a key partner to veterinary practices. Its portfolio comprises veterinary medicines, nutraceuticals and care products in areas such as the gastrointestinal tract, kidneys and urinary tract as well as the cardiovascular system. alfavet operates its own production facility in Neumünster and thus also acts as a contract manufacturer and development partner (CDMO) for third-party customers. Konstantin Wree has led the company as CEO since the beginning of 2025.

The animal health market is growing structurally, driven by the increasing humanisation of pets, their longer life expectancy and the resulting rise in age-related conditions, as well as the growing acceptance of complementary feed products among veterinarians as a supplement or alternative to conventional therapies.

Together with NORD Holding, alfavet is set to grow into the leading European animal health platform over the coming years, primarily through expansion into selected European markets and targeted acquisitions to broaden the product portfolio and open up new markets.

Konstantin Wree, CEO and shareholder of alfavet, comments: “For more than 20 years, veterinarians have relied on alfavet when it comes to the health of their patients. We want to further strengthen this trust in Germany and earn it in additional European markets going forward. In NORD Holding, we have found apartner who shares our growth plans and provides us with the means to implement them both organically and through targeted acquisitions. I am delighted to continue shaping this next chapter as CEO and shareholder.”

For further information, please visit: www.alfavet.de

‍